Bailitianheng announced that it has recently received the Drug Clinical Trial Approval Notice officially issued by the National Medical Products Administration(NMPA). The clinical trial of BL-M17D1 (ADC), an innovative biological medicine independently developed by the company, has been approved.
百利天恒：注射用BL-M17D1（ADC）项目治疗晚期实体瘤获得I期临床试验批准通知书
Baili Tianheng: BL-M17D1 (ADC) project for injection treatment of advanced solid tumors has obtained the approval notice for Phase I clinical trials.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.